AstraZeneca logo
AstraZeneca
AZNCF | OTC
Chart Builder DCF Calculator
$189.90
-$2.60 (-1.35%)
At close: Oct 28, 2025, 3:47 PM ET

AstraZeneca Company Profile

Company profile explained

Company Profile

AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. This encompasses a robust selection for oncology, featuring key treatments such as Calquence, Enhertu, and Tagrisso, alongside vital therapies for cardiovascular, renal, and metabolic conditions, including Farxiga/Forxiga and Brilinta/Brilique. Its offerings further extend to impactful medications for respiratory and immunological ailments like Symbicort and Fasenra, as well as specialized remedies for rare diseases, notably Soliris and Ultomiris. Beyond these primary categories, AstraZeneca's product range includes solutions for infectious diseases, such as Synagis for RSV and the COVID-19 vaccines Vaxzevria and Evusheld, in addition to treatments for neurological disorders like Seroquel and gastrointestinal issues epitomized by Nexium. AstraZeneca distributes its pharmaceuticals to medical practitioners in both primary and specialty care settings worldwide, utilizing an extensive network of distributors and local offices throughout the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. The company actively engages in strategic alliances to propel its research and development efforts. Significant collaborations include agreements with Regeneron Pharmaceuticals, Inc., for the creation of small molecule medicines targeting obesity; Neurimmune AG, for developing and commercializing NI006; Ionis Pharmaceuticals, Inc., to advance eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH, for co-discovering novel small molecules for hematological cancers; and Sierra Oncology, Inc., regarding the development and commercialization of AZD5153. Founded in 1992, the company, formerly known as Zeneca Group PLC, rebranded as AstraZeneca PLC in April 1999 and is headquartered in Cambridge, United Kingdom.

Key Executives

Name Position
Pascal Claude Roland Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Andrew Barnett Head of Investor Relations
David Fredrickson Executive Vice-President of Oncology Haematology Business Unit
Iskra Reic Executive Vice President of International
Jeffrey Pott CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Joris Silon President of Bio Pharmaceutical Business Unit - US
Pam Cheng EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Ruth March Senior Vice President of Precision Medicine - R&D Oncology
Ruud Dobber Executive Vice-President of BioPharmaceuticals Business Unit
Susan Mary Galbraith Executive Vice President of Oncology R&D
AstraZeneca
AstraZeneca logo
Country United Kingdom
IPO Date Feb 13, 2009
Industry Drug Manufacturers - General
Sector Healthcare
Employees 94,300
CEO Pascal Claude Roland Soriot

Contact Details

1 Francis Crick Avenue Cambridge CB2 0AA United Kingdom

Stock Details

Ticker Symbol AZNCF
Exchange OTC
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000901832
CUSIP Number n/a
ISIN Number GB0009895292
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.